Wellington Management Group LLP Purchases Shares of 27,491 Xencor, Inc. (NASDAQ:XNCR)

Wellington Management Group LLP acquired a new position in shares of Xencor, Inc. (NASDAQ:XNCR) in the 4th quarter, HoldingsChannel reports. The fund acquired 27,491 shares of the biopharmaceutical company’s stock, valued at approximately $632,000.

Other hedge funds also recently modified their holdings of the company. Pictet Asset Management Holding SA acquired a new stake in Xencor in the fourth quarter worth $247,000. Norges Bank bought a new position in shares of Xencor during the 4th quarter worth about $3,397,000. Loomis Sayles & Co. L P grew its stake in shares of Xencor by 21.3% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company’s stock valued at $25,102,000 after buying an additional 192,080 shares during the period. Prudential Financial Inc. grew its stake in shares of Xencor by 10.7% in the 4th quarter. Prudential Financial Inc. now owns 70,715 shares of the biopharmaceutical company’s stock valued at $1,625,000 after buying an additional 6,810 shares during the period. Finally, Corebridge Financial Inc. increased its position in Xencor by 5.1% in the 4th quarter. Corebridge Financial Inc. now owns 35,946 shares of the biopharmaceutical company’s stock valued at $826,000 after buying an additional 1,743 shares in the last quarter.

Xencor Stock Up 4.7 %

XNCR stock opened at $8.94 on Tuesday. The firm has a market capitalization of $629.93 million, a PE ratio of -2.79 and a beta of 0.90. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a twelve month low of $7.16 and a twelve month high of $27.24. The stock’s 50 day moving average is $12.90 and its 200-day moving average is $19.01.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on XNCR. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.38.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.